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Background: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with severe effects on the functional
ability of patients. Due to the prevalence of 0.5 to 1.0 percent in western countries, new treatment options are a
major concern for decision makers with regard to their budget impact. In this context, cost-effectiveness analyses
are a helpful tool to evaluate new treatment options for reimbursement schemes.
Objectives: To analyze and compare decision analytic modeling techniques and to explore their use in RA with
regard to their advantages and shortcomings.
Methods: A systematic literature review was conducted in PubMED and 58 studies reporting health economics
decision models were analyzed with regard to the modeling technique used.
Results: From the 58 reviewed publications, we found 13 reporting decision tree-analysis, 25 (cohort) Markov
models, 13 publications on individual sampling methods (ISM) and seven discrete event simulations (DES). Thereby
26 studies were identified as presenting independently developed models and 32 models as adoptions. The
modeling techniques used were found to differ in their complexity and in the number of treatment options
compared. Methodological features are presented in the article and a comprehensive overview of the
cost-effectiveness estimates is given in Additional files 1 and 2.
Discussion: When compared to the other modeling techniques, ISM and DES have advantages in the coverage of
patient heterogeneity and, additionally, DES is capable to model more complex treatment sequences and
competing risks in RA-patients. Nevertheless, the availability of sufficient data is necessary to avoid assumptions in
ISM and DES exercises, thereby enabling biased results. Due to the different settings, time frames and interventions
in the reviewed publications, no direct comparison of modeling techniques was applicable. The results from other
indications suggest that incremental cost-effective ratios (ICERs) do not differ significantly between Markov and DES
models, but DES is able to report more outcome parameters.
Conclusions: Given a sufficient data supply, DES is the modeling technique of choice when modeling cost-effectiveness
in RA. Otherwise transparency on the data inputs is crucial for valid results and to inform decision makers about
possible biases. With regard to ICERs, Markov models might provide similar estimates as more advanced modeling
techniques.
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In most industrialized countries the financial burden of
financing health care systems has increased over the last
years due to the rise of chronic diseases in consequence
of demographic changes as well as the progress in the
development of medical technologies. To counteract these
developments, regulatory institutions and decision makers
have a growing demand for transparent and valid informa-
tion on the relative value of innovations in comparison to
established technologies. Therefore data on relative effi-
cacy as well as effectiveness with respect to specific patient
populations today is expected by regulators and payers
in the major markets to support the decision on whether
to include a new treatment option into reimbursement
schemes and treatment guidelines.
In this context different techniques for conducting
cost-effectiveness analyses (CEAs) surfaced over the last
15 years, enabling a comparison of (incremental) costs
and outcomes of new interventions vs. existing compara-
tors or competitors. Thereby the field of modeling offers
a variety of different methods allowing for an estimation
of even long-term impacts of certain treatments on the
course of a disease beyond the time of clinical studies.
[1]. These different approaches might have different pros
and cons, e.g. with respect to the method itself and also
in specific diseases, which needs to be considered by
regulators and decision makers [2].
Over the past 15 years rheumatoid arthritis (RA) has
been one of the most competitive disease areas with the
introduction of new treatment strategies, e.g. various
biologic therapies, leading to a broad body of literature
on health economic research. Therefore, the aim of the
present review is to explore the field of cost-effectiveness
modeling in RA with respect to the different methods
used. In this context strengths and weaknesses with re-
spect to appropriate modeling approaches with respect
to the course of RA itself as well as a comprehensive
provision of treatment strategies are examined. Finally,
some recommendations on the interpretation of the re-
sults from different modeling types or approaches and
potential advantages of certain modeling techniques in
future studies are given.Methods
To identify developments for the use of modeling tech-
niques in RA, a systematic literature search was con-
ducted January 14, 2014 in PubMED via Medline using
“Medical Subject Heading” (MeSH) terms. The search
yielded 1,074 hits for (“Arthritis, Rheumatoid” [Mesh]
AND “Economics” [Mesh]) with no filters or limitations
applied. The review process is depicted in Figure 1. Pub-
lications were excluded if they were not using modeling
techniques or not applied to specific treatment options.Publications were included if patients with RA were
part of the study population.
Identified systematic reviews were used for cross valid-
ation of identified studies. The main focus of the review
process was to identify analysis techniques applied in the
modeling of the course of RA treatment. Firstly, the
publications were categorized by modeling technique,
country and year and screened for information on spe-
cific modeling parameters (e.g. cycle length). Secondly,
clinical measures used to describe the course of the dis-
ease within the model were extracted and supplemented
by the measurements used to reflect changes in those
health states. Additionally, the sources of the efficacy data
and the base-case results were extracted and are presented
in Additional files 1 and 2.
Rheumatoid arthritis
Epidemiology
Rheumatoid Arthritis (RA) is an inflammatory, auto-
immune disease of chronic course with unknown eti-
ology. The prevalence of RA is estimated to range be-
tween 0.5 to 1 percent in western populations whereby
women are more often affected by the disease with a ra-
tio of 3:1. Concerning the incidence, there is some evi-
dence of a decreasing RA rate due to a later onset of the
disease [3]. Nevertheless, increased mortality of RA pa-
tients in comparison to the general population remains
unchanged and the gap may be even increasing [4].
Etiology of the disease
The clinical course of the disease usually starts with un-
specific symptoms like increasing exhaustibility, anorexia
and weight loss, followed by specific symptoms of pain-
fully swollen joints. Usually, the affection of joints occurs
in a symmetrical manner and mostly affects joints of the
hands and knees. As movement, stretching and pressure
aggravate pain, patients tend to take a relieving posture
often resulting in stiffness of the affected joints [5]. The
course of the disease is characterized by periodic phases
of higher and lower disease activity, which can be mea-
sured via the Disease Activity Score (DAS) or the DAS
with 28-joint count (DAS28) [6]. The disease state can
be classified using the scoring system published by the
American College of Rheumatology (ACR) [7] (see also
newest version from Alehata et al. (2010) [8]). In the
long run, the chronic inflammation leads to damaged
joints and destruction of cartilage [9]. Thereby, the func-
tional disability of RA patients increases on a diminish-
ing scale and is often measured via the disability index
of the Health Assessment Questionnaire (HAQ). The HAQ
is one of the standard domain specific quality of life instru-
ments in rheumatology that gives a detailed impression of
specific functional impairments adding to the burden of
disease [10,11]. A premature mortality of RA is primarily
Figure 1 Flow diagram of the conducted systematic review in PubMED. Background colors represent the different modeling techniques (blue = decision
trees, yellow =Markov models, orange = ISM, green =DES) and bold letters and bright colors indicate an independently developed model.
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of anti-rheumatic drugs [12].
Treatment options and treatment guidelines
In general, treatment options for RA include patient
education, pharmacotherapy, physiotherapy and surgery
[13]. Within pharmacotherapy, drugs can be distinguished
into Disease-Modifying-Anti-Rheumatic-Drugs (DMARDs)
and symptom relief medications such as corticosteroids.
DMARDs are recommended as monotherapy for patients
with early RA in remission or with low disease activity oras combinational therapy in patients with established RA
[14]. Among the DMARDs, so-called biologics (e.g. anti-
TNF compounds) play a major role today in the treatment
algorithm of active RA patients. The American College of
Rheumatology (ACR) treatment guidelines recommend
different strategies for RA patients depending on the time
since onset of disease (early vs. established RA), the grade
of disease activity (low, moderate or high) and whether
the patient is with or without poor prognosis [14]. Disease
activity should be reassessed at regular intervals and drug
treatment should be modified or switched in the case of
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More or less the same approaches to treatment are recom-
mended by guidelines of The European League Against
Rheumatism (EULAR).
Treatment of RA undoubtedly has become more effica-
cious after the introduction of biologic treatment alterna-
tives but it has also become a major area of concern to
health care payers when it comes to the budget impact. In
such scenarios it is of paramount importance to explore
relative cost effectiveness of different alternatives or ap-
proaches to treatment to sort out viable options not only
for health care payers, but ultimately also for patients who
usually have to finance the health care system one way or
the other.
Health economic modeling techniques
Health economic models are common tools for decision
analyses in health administrative bodies and are increas-
ingly used in health economic research. Hereby, different
model types might be distinguished from relative simple
models such as decision trees to more advanced modeling
exercises (e.g. agent-based models). Nowadays one of the
most commonly used model type is that of a Markov-
model.
Decision trees
The most simplistic model type used in health econom-
ics is the decision tree. Within a decision tree the course
of a disease is displayed as a hierarchical, one-directional
tree with either a chance node or a terminal node at the
end of each branch. These models can either be con-
structed for single patients or cohorts, but without the
possibility of interaction between individual subjects.
Nevertheless, decision trees only allow for the analysis of
fixed time frames, making the approach problematic in
use for diseases with varying length in certain health
states. Furthermore, to encounter heterogeneity between
patient-groups, input parameters need to be changed
and the model needs to be run separately for every
subgroup.
Markov models
In health economic Markov-chain modeling, the course
of a disease is described by (various) discrete health
states. Over time, cohorts move through or between
these health states at the end of a cycle of a fixed time
interval. Transition probabilities determine the number
of patients remaining in a health state at the end of a
cycle and also the number of subjects moving to other
connected potential health states. Markov models are
usually run until all patients of a cohort reached an ab-
sorbing state (e.g. death) or maximum number of cycles.
The number of patients over all health states needs to
stay constant in all cycles and patients are only allowedto be in one health state during a cycle [15]. It is also
important to note that there are no interaction or indi-
vidual decisions modeled between the different subjects
in a Markov model. As the disease is mimicked via the
creation of a limited number of distinct health states,
available data needs to be adjusted to represent the clin-
ical course, costs and outcomes at those fixed health
states. Similar to a decision tree Markov models can
analyze subgroups only by adjustment of model parame-
ters and repeated runs of the model to cover questions
of heterogeneity. Although it is possible to cover small
numbers of subgroups of to address questions of hetero-
geneity by additional health states, it is feasible to
analyze high numbers of subgroups by repeated runs of
the model with different parameter sets for technical
boundaries.
Individual Sampling Methods (ISM)
Another method to address problems of heterogeneity is
to use individual sampling models [1]. In accordance to
Markov models, individual sampling models or Monte
Carlo simulations consist of different distinct states, but
as only single patients are sent through the model, attri-
butes of patients may be changed over time thus chan-
ging transition probabilities or other input parameters.
This way individual sampling models overcome the need
for a disproportional number of health states to track
changes over time. For following references in this paper
with respect to this method the main distinction of the
individual sampling method and DES methods is defined
as the use of fixed cycle lengths.
Discrete Event Simulations (DES)
In contrast to the above described modeling techniques,
discrete event simulation (DES) focuses on the treatment
pathway of a patient rather than modeling the course of
the disease itself. In short, single entities (e.g. patients,
health care professionals) with certain attributes (e.g. age,
gender, disease severity) experience certain events (e.g.
disease progression, hospital admission) based on their
attributes, and, as a result of that, experience benefits or
harms and consume resources. A strong emphasis of
DES lies on the modeling of scarce resources and the
behavior of entities competing or waiting for the avail-
ability of those resources [16]. In this context, an inter-
action between entities, e.g. patients, is possible as they
can for example form waiting queues and access re-
sources following pre-defined rules. Also, a main advan-
tage of DES is its capability of the inclusion of patient
characteristics, thus accounting for heterogeneity [16].
Even though DES is one of the more advanced methods
used in health economic evaluation it still has some disad-
vantages attached. Firstly, DES is rather process-oriented
leaving out interactions between entities which are not
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jects in a rather passive role making them flow through
the system instead of letting them decide independently
[17]. Additionally, the higher complexity of the model
comes with a much higher demand on input data, which
in many situation will not be easily accessible (e.g. patient-
level data from clinical trials). Also, the sampling from
distributions for each parameter for a large number of in-
dividuals involves model calibration, which is still under
methodological development.
ISPOR Guidelines on good modeling practice (health
transition modeling and DES-modeling)
Besides the decision tree method, the International So-
ciety for Pharmacoeconomics and Outcomes Research
(ISPOR) provides guidelines for good modeling prac-
tice for each of the above mentioned modeling
techniques. Concerning the choice of the model, the
authors recommend a Markov cohort simulation, if
the number of necessary health states which depict the
health problem remains manageable. If some aspect of
the health problem cannot be reproduced in an appro-
priate way, an ISM modeling exercise should be
chosen, but sequential decisions on treatment options
should not be considered in the same model [18]. DES
is recommended as first choice to model problems
caused by constrained or limited resources. In ad-
dition, DES is seen as being also suitable to model
time to one or multiple events stochastically and con-
sidering many characteristics of a patient influencing
time. Thereby, the trade-off between the detailing of
the model and the availability of data should be
described and changes to the model structure or the
influence of expert opinions filling data gaps should be
explored and reported [19].
Review
Cost-effectiveness modeling in RA
Summary over all identified analyses
Via the literature search n = 58 publications between
1996 and 2012 could be identified. 13 studies used a
decision tree approach, 25 studies Markov-modeling,
13 studies an individual sampling method (ISM) and
the DES-technique was applied seven times. As many
of those studies are adaptations or enhancements of exist-
ing models, a family tree of all publications is displayed in
Figure 2, where publications in bold letters represent the
original model within a tree of references.
With 12 out of 25 studies, the highest number of inde-
pendently developed models can be found for Markov-
models with a similar share of six out of 13 for decision
tree-studies. In contrast, four out of 13 ISMs and three
out of seven DES-studies might be considered independ-
ently developed models.On average the decision tree models have the shortest
time horizons of all model types, besides Moore et al.,
Spiegel et al. and Zabinski et al. apply a life-time horizon
[20-22]. The Markov models range from one year to life-
time mostly applying a six month cycle length (three to
twelve months), whereas the DES and ISM models, with
one exception, take a life-time perspective. A summary
of study characteristics can be found in Table 1 (sorted
by model type).
As can be seen in Table 2 decision tree models tend to
compare treatment strategies involving etanercept, aba-
tacept, adalimumab and methotrexate. Markov models
focus on methotrexate, an unspecified TNF-biologic or
gold. Individual sampling models mostly involve metho-
trexate and rituximab/methotrexate. Compared to the
overall number of models, DES models are evaluating a
much higher number of treatment strategies as more often
treatment patterns or pathways are modeled. Eleven of the
DMARD strategies as well as 14 TNF-alpha-antagonist
strategies compared are not further specified.
Description of Models by Modeling Technique
Decision Trees
The earliest model included in this review is the decision
tree analysis of Kavanaugh et al. [23], which has also
been used by Choi et al. [24] and Choi et al. [16]. The
decision tree splits up after choice of treatment. For each
treatment, side-effects (minor and major) may occur. If
no side-effects emerge a patient can either (partially or
fully) respond or not respond following ACR criteria.
For patients with minor side-effects it is also possible to
respond to the treatment. The time-horizon is six months.
Choi et al. [24] and Choi et al. [16] performed only de-
terministic sensitivity analyses, whereas Kavanaugh et al.
[23] used Monte-Carlo simulation for one-way sensitivity
analysis.
The second family of decision tree models was built by
Russell et al. [25], Beresniak et al. [26], Cimmino et al.
[27], Puolakka et al. [28], Saraux et al. [29] and Beresniak
et al. [30]. The trees depict the treatment of patients
within four six-month intervals starting with a TNF-alpha-
antagonist. After each interval patients either show signs
of remission, in which case they stick with the current
treatment, or they change to the next intervention. In all
publications the DAS28 score is used to define effective-
ness using the low-disease activity state (DAS28 ≤ 3.2) as
primary end-point describing cost-effectiveness. Besides
Beresniak et al. [30], all models perform probabilistic
sensitivity analysis and all six models report an ICER for
costs per day in a low disease activity state with confi-
dence intervals.
Chiou et al. [31] use an independent decision tree-
model to evaluate the cost-effectiveness of several bio-
logic response modifiers. Similar to the Russell-models,
Figure 2 Family tree of analyzed publications. Background colors represent the different modeling techniques (blue = decision trees, yellow = Markov
models, orange = ISM, green = DES) and bold letters and bright colors indicate an independently developed model.
Scholz and Mittendorf Health Economics Review 2014, 4:18 Page 6 of 16
http://www.healtheconomicsreview.com/content/4/1/18intervals of six months are used for a total time horizon
of one year. After the first six months the effectiveness
of an intervention is measured using ACR response
criteria categorized into no ACR, ACR20, ACR50 and
ACR70 responses. After the second interval it is pos-
sible that patients develop no, mild, moderate or severe
complications. Only deterministic, one-way-sensitivity
analysis is performed.
In the publication by Spiegel et al. [21] a decision tree
is applied to the question whether rofecoxib and cele-
coxib are cost-effective compared to non-selective non-
steroidal anti-inflammatory drugs (NSAIDs) in the treat-
ment of chronic arthritis. Over a life-time time horizon,
the number of gastrointestinal (GI) complications, i.e.
dyspepsia, ulcer bleeding and ulcer perforation, is mod-
eled for each of the alternatives. Hence, the model does
not focus on the efficacy of the alternatives on RA, but onthe reduction on adverse events. The cost-effectiveness
measure is calculated as incremental costs per QALY. A
meta-analysis is used to obtain parameters for clinical
efficacy and PSA is performed.
In a similar study, Zabinski et al. [22] compared cele-
coxib alone vs. several NSAIDs in osteoarthritic (OA)
and RA patients, also focusing on adverse events follow-
ing these treatments. Thereby gastrointestinal events are
supplemented by “anaemia with occult bleeding”. The
analysis is carried out for a time-horizon of 6 months and
calculates costs from a third-party payer-perspective, but
no ICER.
The decision tree constructed by Moore et al. [20]
compares etoricoxib with several NSAID-strategies. Again,
the main health states comprise gastrointestinal adverse
events (“GI problems”, “no GI problems”), but with a
more complex depiction of the following treatment
Table 1 Summary of study characteristics
Publication Model type Perspective Cycle length Time horizon DAS PSA Efficacy measure Clinical measure
Beresniak 2011
[26] Spain










Decision Tree TTP 6 months 1 year Yes No ACR ACR/VAS-Score
Choi 2000
[24] USA
Decision Tree Societal Not applicable 6 months Yes No ACR -
Choi 2002
[16] USA









Decision Tree Not stated
(Societal)














Decision Tree TTP ?6 months 2 years No Yes Effect on DAS-Score DAS-Score
Saraux 2010
[29] France






























Markov Model Not stated
(Societal)




[34] Sweden & UK




[32] Sweden & UK
Markov Model Not stated
(Societal)





Markov Model not stated not stated 10 years No Yes not stated HAQ Score & VAS Score
Kobelt 2005a
[36] Sweden

























Markov Model TTP 6 months 5 years No Yes - ACR20 Response
Maetzel 2003
[48] Canada
Markov Model TTP 3 months 5 years Yes No Reduction in
Complications
Complications
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Table 1 Summary of study characteristics (Continued)
Marra 2007
[52] Canada





Markov Model TTP 3 months 5 years Yes Yes - ACR50 Response
Schädlich 2004
[55] Germany
Markov Model TTP 6 months 3 years Yes No - ACR20 Response
Schipper 2011
[42] The Netherlands










Markov Model Not stated
(Societal)
6 months Life-time Yes No ACR HAQ-Score
Welsing 2004
[41] The Netherlands
Markov Model not stated 3 months 5 years Yes Yes EULAR &ACR DAS-Score
Wong 2002
[43] USA





Markov Model TTP 6 months Life-time Yes Yes - ACR20/50/70 Response
Yun 2005
[47] Korea







6 months Life-time Yes Yes ACR HAQ-Score
Brennan 2004
[15] UK
ISM Societal 6 months Life-time Yes No ACR HAQ-Score
Brennan 2007
[58] UK
ISM TTP 6 months Life-time Yes Yes EULAR HAQ Score
Diamantpoulus 2012
[68] Italy
ISM TTP 6 months Life-time Yes Yes - ACR20/50/70 Response
Finckh 2009
[60] USA










ISM TTP 6 months Life-time Yes Yes ACR HAQ Score
Merkesdahl 2010
[62] Germany
ISM TTP 6 months 100 years Yes Yes ACR HAQ-Score
Soini 2012
[64] Finnland
ISM Societal 6 months Life-time Yes Yes ACR HAQ Score
Vera-Llonch 2008
[65] USA










ISM TTP 6 months Life-time Yes Yes ACR HAQ-Score
Yuan 2010
[67] USA




















DES Not stated Not applicable Life-time Yes No Effect on HAQ-
Score
HAQ-Score
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Table 1 Summary of study characteristics (Continued)
Kobelt 2009
[74] Sweden










Not applicable Life-time Yes Yes Effect on HAQ-
Score
HAQ-Score
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patients, but also OA-patients were included in the popu-
lation of the analysis. An ICER from the perspective of the
NHS is reported including deterministic and probabilistic
sensitivity analysis.
Markov models
The most adopted Markov-model is from Kobelt et al.
[32], which is based on two earlier works also from
Kobelt et al. [33,34]. Those studies are not included in
this review as only hypothetical treatments are evaluated
to justify the general use of Markov models in RA in
those two studies. The authors built a model using seven
states corresponding to HAQ-scores also including
death with a time horizon of 10 years and a cycle-length
of one year. In difference, the following studies by Kobelt
et al. [35] and Kobelt et al. [36] reduced the number of
disease states by one. Further, in the paper from 2011,
Kobelt et al. [37] use a cycle length of six months and
Lekander et al. [38] extended the time-horizon to
20 years. All following studies subdivided each health
state by a high or low VAS-Score or high or low disease-
activity measured by the DAS28-score. Whereas Kobelt
et al. [32] analyze the cost-effectiveness of infliximab,
the model from Kobelt et al. [36] does not evaluate the
cost-effectiveness of a specific drug, but constitutes an
advancement compared to Kobelt et al. [34]. Kobelt
et al. and Kobelt et al. investigate the cost-effectiveness
of etanercept in combination with methotrexate and eta-
nercept monotherapy. In addition, Lekander et al. ex-
tended this analysis by grouping TNF-alpha-inhibitors
and Lekander et al. [40] analyzed the cost-effectiveness
of infliximab. Another application of the model com-
pared the results of the model for three different trial
cohorts (Lekander et al. [39]). From Kobelt et al. on,
probabilistic sensitivity analyses (PSA) has been used
[39,40].
Welsing et al. [41] and Schipper et al. [42] are using
the four Markov-states “remission”, “low disease activity”,
“moderate disease activity” and “high disease activity”
corresponding to DAS28-scores, although with different
classifications. Patients may change the treatment after
inadequate response. Both studies use a cycle length of
three months and a time horizon of five years. PSA wasperformed using 1,000 iterations or 1,000 patients,
respectively.
The original Markov-model from Wong et al. [43] has
later been adapted by Barbieri et al. [44] for a longer
time horizon. In both models, four different health states
are defined using HAQ-scores for each of the five treat-
ment options, thus resulting in 21 health states with the
inclusion of death. The models extrapolate the results of
the ATTRACT trial for infliximab from 54 weeks to a
life-time horizon using a cycle length of six months. The
first model has been validated in an earlier publication.
[45] No PSA was performed.
Bae et al. [46] developed a first model for Korea to exam-
ine the cost-effectiveness of corticosteroids compared to
NSAIDs and COX-2 inhibitors in RA patients. Over a life-
time patients are moving through seven corticosteroid-
specific or seven NSAID-specific complication-health states
and the absorbing “death”-state in twelve month cycles. An
ICER is given as costs per QALY and a deterministic sensi-
tivity analysis was performed. The model has been adopted
by Yun and Bae [47] to compare several NSAID and one
COX-2 treatment strategy. Therefore, the health states
concerning the NSAID-specific complications were kept
in the model and supplemented by health states depicting
treatment patterns.
In their first publication Maetzel et al. [48] focus on
RA patients alone and the cost-effectiveness of adding
leflunomide to a treatment sequence of DMARDs in
Canada. The health states are divided into “ACR20-re-
sponse” or “no ACR20-response” leading to continuation
of current treatment and “severe AE” or “lack of efficacy”
leading to the next treatment in the sequence. The result is
given as an ICER (costs per QALY) and uncertainty is cap-
tured by probabilistic sensitivity analysis. In their second
study, Maetzel et al. [49] analyze the cost-effectiveness of
NSAIDs compared to COX-2 inhibitors. GI events are
modeled for OA or RA patients over 12 health states, each
supplemented by a decision tree reflecting the treatment
pattern following the specific health state. The ICER is
calculated as costs per QALY from a third-party payer
perspective and only a deterministic sensitivity analysis
is performed.
The model by Spalding et al. [50] includes three differ-
ent Markov-states. Patients start with a specific first-line
Table 2 Agents used in the model overall and differentiated by model type
Abbreviation Full name Overall Decision trees Markov models ISM DES
ABA Abatacept 13 12 0 1 0
ABA/MTX Abatacept + Methotrexate 11 0 0 10 1
ADA Adalimumab 29 20 3 2 4
ADA/MTX Adalimumab +Methotrexate 20 1 2 13 4
ANA Anakinra 1 1 0 0 0
ANA/MTX Anakinra + Methotrexte 9 1 0 0 8
AZA Azathioprine 48 0 8 0 40
BSC Best Supportive Care 47 0 1 18 28
BSC/MTX Best Supportive Care + Methotrexate 4 0 0 4 0
BUC Bucillamine 2 0 2 0 0
CEL Celecoxib 3 0 3 0 0
CER/MTX Certolizumab +Methotrexate 1 0 1 0 0
COR Corticosteroid 1 0 1 0 0
COX-2 selective COX-2 inhibitor 2 0 2 0 0
CYC Ciclosporin 60 0 9 11 40
CYC/MTX Ciclosporin + Methotrexate 35 1 0 0 34
DIC Diclofenac 1 0 1 0 0
DMARD any Disease-Modifying-Anti-Rheumatic-Drug 11 3 3 5 0
ETA Etanercept 48 26 7 3 12
ETA/MTX Etanercept + Methotrexate 18 2 3 9 4
ETO Etoricoxib 1 1 0 0 0
GOL/MTX Golimumab +Methotrexate 1 0 1 0 0
Gold 66 1 17 8 40
HCQ Hydroxychloroquine 12 0 0 0 12
HCQ/MTX Hydroxychloroquine +Methotrexate 20 1 8 0 11
IBU Ibuprofen 1 0 1 0 0
INF Infliximab 19 8 4 4 3
INF/MTX Infliximab + Methotrexate 36 1 8 11 16
LEF Leflunomide 66 1 16 9 40
LEF/MTX Leflunomide + Methotrexate 1 0 1 0 0
MTX Methotrexate 115 10 41 30 34
NAP Naproxen 2 1 1 0 0
NSAID (nonselective) nonsteroidal anti-inflammatory drugs 5 1 4 0 0
NSAID/H2RA NSAID + H2 receptor antagonist 1 1 0 0 0
NSAID/MIS NSAID +Misoprostol 2 1 1 0 0
NSAID/PPI NSAID + proton pump inhibitor 3 1 2 0 0
PEN Penicillamine 22 0 0 0 22
PRD/MTX Prednisone/Prednisolone 0 0 0 0 0
ROF Rofecoxib 1 0 1 0 0
RTX Rituximab 14 7 6 0 1
RTX/MTX Rituximab + Methotrexate 21 0 0 20 1
SUL Sulfasalazine 48 2 10 2 34
SUL/HCQ/MTX Sulfasalazine + Hydroxychloroquine +Methotrexate 14 1 2 0 11
SUL/MTX Sulfasalazine + Hydroxychloroquine 20 0 4 0 16
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Table 2 Agents used in the model overall and differentiated by model type (Continued)
TNF TNF-inhibitor 14 1 9 2 2
TOC/MTX Tocilizumab + Methotrexate 3 0 0 3 0
OVERALL 872 106 183 165 418
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state or to death from either of the two other states. For
each of the two treatment states certain costs and a
specific reduction in the HAQ-score are assumed per
12 month cycle. Again, no PSA was conducted.
Tanno et al. [51] are presenting the only model for
Japan. Similar to the model family around Kielhorn et al.
[61], the Markov-states represent the treatment options
and patients move in six months cycles to the next treat-
ment in sequence, if they fail an ACR20 response. The
authors include age- and sex-specific excess mortality
due to RA as an exponential function of the HAQ-score.
Patients are also assumed to have failed an initial ther-
apy with bucillamine, whereas the main interest is in the
cost-effectiveness of etanercept. Only one-way sensitivity
analyses were performed and reported as tornado-plot.
The first intention of Marra et al. [52] lies in the cost-
effectiveness of infliximab in combination with methotrex-
ate compared to methotrexate monotherapy. Secondly,
the authors also explore the influence of different quality
of life questionnaires (HUI-2, HUI-3, SF-6D, EQ-5D) on
health utility and therefore on cost-effectiveness. Within a
time-horizon of 10 years patients move between 25 health
states, as defined corresponding to HAQ-scores from zero
to three in steps of 0.125 (similar to the BRAM approach
described later) plus death in cycles of one week. PSA was
performed and the differences between the different ques-
tionnaires are clearly demonstrated.
Nguyen et al. [53] present a similar but independently
developed model to Spalding et al. [50]. In the model,
patients start with the treatment of one of five different
TNF-α antagonists in the first health state and either
move to the ACR50-response health state or a non-
response health state. Patients in the non-responder health
state are assumed to switch to tocilizumab as second-line
treatment. Patients can die from all three health states.
The cycle length of the model is three months and the
time horizon is five years. One-way deterministic as well
as probabilistic sensitivity analyses were applied.
The study of Bessette et al. [54] compares celecoxib as
1st, 2nd and 3rd line treatment option in addition to differ-
ent NSAID-strategies. In similarity to other studies with a
comparable research question, the health states consider
mainly GI events supplemented by one health state for
cardiovascular AEs. In the case of an AE, patients con-
tinue to the next treatment option in the sequence. Of all
Markov-models Bessette et al. are using the shortest cycle
length with one month (time-horizon: five years).The German publication from Schädlich et al. [55] re-
ports the results from an adaption of the “The Avara®
interactive model”, on which no further information or
publication could be found. The cost-effectiveness of add-
itional leflunomide in four different DMARD-treatment
sequences is analyzed using ACR20-response to differenti-
ate the health states. The model is run for six cycles of six
months cycle length. The ICER for each sequence with
leflunomide is calculated for the corresponding sequence
without leflunomide.
Wu et al. [56] report the only cost-effectiveness model
found for China comparing seven different treatment
sequences. Health states are defined using ACR20/50/70
response criteria and the next treatment option in the
particular sequence is selected after poor remission or
adverse events. The results are presented as costs per
QALY in a cost-effectiveness frontier. Deterministic as
well as probabilistic sensitivity analyses are performed.
Individual sampling models
Brennan et al. [15] developed the first individual sam-
pling model. Thereby, certain events for patients of a
certain age, sex and HAQ-Score are calculated using
fixed time intervals of six months for DMARDs and
three months for etanercept, respectively. In detail, pa-
tients who failed two conventional DMARDs are as-
sumed to receive a certain treatment which might lead
to a response according to the ACR20 criteria, thus
continuing treatment until loss of efficacy or an ad-
verse event, no response or death. The responders may
continue the treatment and non-responders move on
to the next treatment in sequence. Costs and utilities
for each patient are documented during the modeling
process. Bansback et al. [57] describe a slightly modi-
fied model for Sweden, where adverse events and the
loss of efficacy are explicitly included in the first cycle
in which patients receive a new treatment. Brennan
et al. [58] use their model from 2004 with data from
the British Society for Rheumatology Biologics Registry
(BSRBR) for 8,000 patients and Wailoo et al. [59] with
data from the National Database of Rheumatic Diseases
(NDB) for 10,000 US-patients. The latter model has been
modified by Finckh et al. [60] to compare three different
treatment strategies including DMARDs (conventional and
biologic) and other pharmaceutical and non-pharmaceutical
interventions.
In the individual sampling-model by Kielhorn et al. [61]
patients start after inadequate response to two biological
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ment sequence. For each treatment patients may enter five
different health states (including death) defined by the
ACR-Score and move to the next treatment if they show
no response. If they completed all treatment options pa-
tients move to a palliative care state. The time-horizon is
100 years with a cycle-length of 6 months. Merkesdal et al.
[62], Hallinen et al. [63] and Soini et al. [64] are using the
same model structure for country specific analyses. The
analyses were conducted using 10,000 patients and 3,000
patients in both Finnish studies, respectively. Additionally,
PSA was performed using 1,000 iterations in all models.
Vera-Llonch et al. [65] and Vera-Llonch et al. [66] lean
their individual sampling models against Brennan et al.
[58]. Both studies are evaluating the cost-effectiveness of
abatacept, using data from the clinical AIM or ATTAIN
trials with methotrexate or an unspecified DMARD as
comparator, respectively. Patients in the model who are
assumed to start treatment with abatacept are consid-
ered to continue on treatment after 6 months of therapy
if they show a HAQ-score improvement of at least 0.50,
no side-effects (no cost and utility affects assumed), no
co-morbid conditions and no surgery. The model analyses
costs and QALYs of 1,000 female patients between 55 and
64 years over ten years and life-time with a cycle length of
three months. Changes on HAQ-scores were considered
as multiples of 0.125. The models were adopted by Yuan
et al. [67] to analyze the cost-effectiveness of abatacept
and rituximab.
The only non-adopted ISM was done by Diamantopoulus
et al. [68]. The model was developed to evaluate the
cost-effectiveness of tocilizumab in addition to a se-
quence of DMARDs and TNF-inhibitors from an Italian
third-party payer perspective. 10,000 patients are followed
over a life-time. Treatment efficacy is measured via the
ACR20/50/70 response criteria and patients continue to
the next treatment option after no response. ICERs are
calculated for all sequences and deterministic as well as
probabilistic sensitivity analyzes are performed.
Discrete event simulations
Most DES models are developed for the United Kingdom
and used within the Health Technology Assessment
process. The first DES model has been developed by
Jobanputra et al. [69] to assess the cost-effectiveness of
infliximab and etanercept and is known as the Birmingham
Preliminary Model (BPM). Within the model, the time of
an individual patient on a certain DMARD in a sequence
of DMARDs is calculated and all corresponding costs and
health outcomes are documented. Afterwards, depending
on the remaining lifetime of a patient, the patient moves
to the next treatment option or dies. For some treatments
effects of certain toxicities are included in the model
which may lead to changes in the treatment cascade.Barton et al. [70] extended the model by allowing pa-
tients to stop the current treatment not only by continu-
ing with the next DMARD in sequence or death, but also
by undergoing a joint replacement and/or an increase in
the HAQ-Score. Thereby, in order to decide which event
occurs and ends the treatment, the time of each event is
calculated separately and the event with the shortest time-
frame is taken into account. Changes in the HAQ-score
are modeled with an interval of 0.125.
Clark et al. [17] are using the Birmingham Rheumatoid
Arthritis Model (BRAM) from Barton et al. to evaluate
the cost-effectiveness of anakinra. Chen et al. [71] also use
the BRAM for adalimumab, etanercept and infliximab,
although joint replacements are left out of both latter
models. The later adaption by Chen also includes individ-
ual improvements on HAQ-scores and early withdrawal
from a treatment by patients is considered. The last adap-
tation of the BRAM is used by Malottki et al. [72] which
made further improvements to the model by allowing for
a non-linear translation of HAQ-scores to utility values
and enabling probabilistic sensitivity analysis.
With the work from Lindgren et al. [73] only one
non-UK DES-model could be identified. The authors
analyze the cost-effectiveness of rituximab as second
biologic agent in different treatment sequences. As with
the BPM and BRAM, patients may be on or off treat-
ment or dead, although the evaluated treatment se-
quences only include TNF-alpha-antagonists thus being
shorter than in other DES models. When patients are
on treatment they are either in a high or low DAS28
state and change to other states by treatment discontinu-
ation, re-initiation, changing disease activity or death. The
model was filled with data from the REFLEX trial and the
SSATG-database. The model has been adopted by Kobelt
et al. [74] with no major changes to analyze costs and out-
comes for one sequence.
Discussion
The present review analyzed 58 studies reporting cost-
effectiveness modeling exercises on RA. The number of
models using decision trees, Markov or ISM methods does
not vary significantly, with fewer models using DES, but
no trends in time could be observed with respect to a
preferential use of certain model-types. Nevertheless, a
higher number of Markov models are reported as inde-
pendently conducted CEAs, whereas decision trees, ISM
and DES tended to be adopted more often. This might be
due to the increasing complexity and the higher computa-
tional requirements of ISM and DES when compared to
the relatively wide-spread use of Markov models in health
economic research.
Besides Lindgren et al. [73] and Kobelt et al. [74],
all DES studies primarily have been developed for the
UK and were published as part of a health technology
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reviewed that are submitted by a pharmaceutical com-
pany to the National Institute for Clinical Excellence
(NICE). The background given in the HTAs for the
development of the Birmingham Preliminary Model
(BPM) [64] and its updated versions – known as the
Birmingham Rheumatoid Arthritis Model (BRAM) – is
the ability of DES to more accurately depict compre-
hensive treatment sequences as they occur in RA pa-
tients (see Table 2) and a more flexible course of the
disease. Barton et al. [70] also puts a strong emphasis
on the timing on activities and how the BRAM deals with
competing risks. [65] On the other hand an impending
need for reliable data is stated, especially impact patterns
on quality of life under certain treatments [64].
With regard to the differences in time and the different
settings and perspectives, no valid direct comparisons be-
tween the results of the different modeling techniques
could be performed and no publications could be iden-
tified performing a direct comparison between different
methodologies with the same input data. However, two
studies comparing DES and Markov models in HIV and
depression could be found, respectively. Summarizing,
Simpson et al. [75] report no considerable differences in
the ICERs for a time-frame from five to ten years. How-
ever, as the DES model is capable to simulate a higher
number of clinical parameters for HIV patients it seems
to have a slightly better predictive ability than the Markov
model, when the findings are compared to real life
data. For depression, Le Lay et al. [76] compared a self-
developed DES model with Markov models the authors
identified in the literature. Though no ICERs are com-
pared in the study, the authors also report the DES
model to be able to incorporate more factors relevant
to the treatment of depression than the Markov model,
especially the patients’ history and their attitude towards
different treatment options.
These examples illustrate the advantages DES models
might also provide in their further application for RA.
Under the consideration of their weaknesses, an even
higher need (and mostly lack thereof ) for reliable data
and the resulting increased incorporation of expert
opinion or even assumptions [2], a wider spectrum of
outcome parameters might be presented to regulators
as well as other decision makers. This could be a bene-
fit but also a disadvantage, depending on the willing-
ness of individual decision makers to look at even more
complex data sets. Nevertheless, in any case it will be
possible to reduce the wider variety of results from a
DES to the information depth that usually comes with a
Markov model.
However, the selection of the most appropriate model
type, and therefore which simplification of reality is chosen,
is a lively discussion. Even as there are guidelines on modelselection (see for example [1,77]), following different
guidelines may lead to different model types. Further-
more, questions on the relevance of certain parameters
might be answered differently by modelers working on
the same decision analytic problem, also leading to dif-
ferent approaches. Though simplicity is an advantage in
models, if complex modeling techniques are available to
tackle complex decision problems (e.g. life-time treat-
ment sequences in RA) those model types should be ap-
plied [1]. In this context, the consideration of patient
heterogeneity in economic evaluations [78] further en-
courages the use of more complex modeling techniques
like DES [79].
Besides the models following Russell et al. [25], which
use costs per day of low-disease activity score (LDAS),
all models reviewed use a costs per QALY approach.
The use of QALYs as their main outcome is justified
with recommendations of regulatory bodies or with better
comparability with other studies. In this context the bur-
den of the disease might be modeled more comprehen-
sively by the inclusion of necessary non-pharmaceutical
treatments and socioeconomic consequences of the dis-
ease. In future studies also structural limitations in the
health care provision for RA patients may be implemented
in DES models. For example, the implications of a de-
creasing number of rheumatologists might be included in
a DES framework using its ability to simulate queues given
a maximal capacity a rheumatologist is able to take care
of. This might also be relevant for time consuming and
resource blocking therapies, such as intravenous infu-
sions including monitoring for several hours or physical
examinations.
Conclusion
In conclusion, Markov models, ISM and DES are appro-
priate choices to model the cost-effectiveness of treat-
ment options for RA patients, whereas decision trees are
only able to produce results for short time horizons. Al-
though ISM overcomes the lack of consideration of het-
erogeneity of RA patients in Markov (cohort) models,
DES is able to produce even more detailed results. This
might come at the cost of more assumptions needing
to be incorporated in the model and decision makers
should be aware of this. Therefore, extensive sensitivity
analyses on input parameters as well as on structural
components of the model and a clear declaration of
data sources are necessary for a valid interpretation of
the results.
The aim of this review was to provide an informative
basis on the advantages and disadvantages of modeling
techniques used to model RA and on the data sources
for clinical parameters (see Additional files 1 and 2). If
sufficient data are available, DES should be considered
as the preferred modeling technique.
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